Mainz Biomed Secures Public Funding for Pancreatic Cancer Screening Project
I'm PortAI, I can summarize articles.
Mainz Biomed NV has secured public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer screening project. The ISB will cover up to 50% of the project's total costs under the Innovation and Technology Support Program. This funding aims to expedite the development of a non-invasive, blood-based test for early pancreatic cancer detection. No other beneficiaries were mentioned.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments